GLEN BURNIE, Md.--(NovaSom, Inc., the leader in home sleep testing and cost-saving solutions for Obstructive Sleep Apnea (OSA) management, announced that Michael Coppola, M.D., President and Chief Medical Officer of the American Sleep Apnea Association, will be joining as Chief Medical Officer and Vice President of Medical Affairs.)--
“Work Group on the Future of Sleep Medicine and the Medical Home.”
Joining NovaSom’s Executive Committee, Dr. Coppola will be leading the development of best clinical practices and provide the benefit of his OSA thought leadership for future product and service development. In addition, he will guide NovaSom’s outreach to specialty and primary care providers, sleep centers, payers, employers, medical societies and advocacy organizations to drive the adoption of cost-effective sleep apnea diagnosis and treatment in an effort to reduce the unacceptably high number of undiagnosed Americans living with the condition.
Dr. Coppola is board certified in Internal Medicine, Pulmonology, Critical Care and Sleep Medicine and is an Associate Clinical Professor at Tufts University School of Medicine. With 30 years of experience addressing the OSA epidemic, Dr. Coppola has been involved with the American Sleep Apnea Association, the nation’s largest non-profit OSA patient advocacy organization, since joining its Board of Directors in 2004. He also spent eight years on the International Medical Advisory Board at ResMed from 1998 to 2006 and is currently a member of the Board of Directors of Health New England, a 100,000 member HMO, and of Baycare Health Partners, a PHO. Additionally, Dr. Coppola has held various roles in professional societies, including the American Academy of Sleep Medicine, where he recently served as Vice Chair on the “Work Group on the Future of Sleep Medicine and the Medical Home.” He has published in numerous scholarly journals, including SLEEP and Sleep and Breathing, and in 1993 published the very first case series involving the use of home sleep testing in Chest. Dr. Coppola is a graduate of Georgetown University Medical School.
Richard Hassett, MD, CEO, NovaSom, said, “Diagnosis is the first step to treatment, and home sleep testing is an important weapon as we address this massive public health epidemic. We must reduce the enormous number of people living with undiagnosed OSA because it’s adversely impacting their health and productivity in the workplace. Dr. Coppola has decades of experience with this condition, and understands how it overlaps and aggravates so many other common conditions, such as diabetes, hypertension, obesity and heart disease. What’s more, he has championed the adoption of home sleep testing for years and understands the challenges that patients, primary care and sleep specialty physicians face. He will be an integral member of our team, especially as we continue to partner with industry and sleep specialists alike, to drive efficient diagnosis and treatment of this dangerous condition.”
Dr. Coppola commented, “NovaSom has established itself as the leader in home sleep testing and I am very pleased to join the executive team. NovaSom’s home sleep testing technology platform enables convenient, cost-effective diagnostic solutions that ensure highly accurate outcomes necessary to appropriately treat this heavily undiagnosed patient population. It has never been more important to expand diagnostic capacity than now, as we confront this massive epidemic and its heavy burden on the healthcare system.”
For more information about NovaSom and home sleep testing, please visit www.NovaSom.com.
Obstructive Sleep Apnea (OSA) affects 40 million Americans, of which 18 million have moderate to severe disease. Of these, a startling 85% of sufferers are undiagnosed and therefore untreated, generating significant medical expense for patients and the healthcare system. Nearly half of all OSA patients also suffer from one or more serious health conditions such as diabetes, hypertension or heart failure that is either aggravated or caused by OSA. Treating OSA reduces medical expenses, improves patient quality of life and lowers associated health risks.
About NovaSom, Inc.
NovaSom, Inc. is the market leader in Obstructive Sleep Apnea (OSA) home testing, with the first FDA-cleared system, NovaSom® Home Sleep Test, and the second generation AccuSom® Home Sleep Test, the first and only FDA-cleared wireless HST. The NovaSom home sleep testing technology and MediTrack® portal have been shown to provide in-home, clinically equivalent diagnosis of OSA at a significantly reduced cost as compared to in-facility testing for uncomplicated, adult OSA. NovaSom’s home sleep tests are currently covered for more than 165 million U.S. lives, through partnerships with major health insurers.
NovaSom also offers comprehensive service programs that are utilized by payers, employers, primary care and sleep specialist physicians nationwide, that enable significant cost savings for OSA management. In an effort to combat the growing OSA epidemic, NovaSom also partners with sleep centers, enabling sleep specialists to offer clinically appropriate patients an alternative, convenient testing option, expanding access to diagnosis and treatment.
NovaSom is accredited by the Joint Commission as an Ambulatory Care Sleep Diagnostic Center and is approved by CMS as an Independent Diagnostic Testing Facility. For more information, visit www.NovaSom.com.
Photos/Multimedia Gallery Available: http://www.businesswire.com/cgi-bin/mmg.cgi?eid=50247619&lang=en